Go Back

Combining data and cancer care expertise to inform the future of cancer care.

Carevive Systems, Inc. founded in 2013, is an oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Our platform enables clinicians to monitor and manage their patients remotely, which improves clinical outcomes and patient quality of life. Use of Carevive in the clinic unlocks critical data on the real-world experience of patients with cancer, to continuously improve patient care today and advance cancer drug development. <br/><br/> <a href="https://www.carevive.com/contact-us/" target="_blank" style="color:#4FAFC9;">Learn more about Carevive here</a><br/>

Carevive

Understanding Carevive SMART Data™

January 1, 2023

In a world inundated with vast amounts of healthcare data, making sense of it all can be overwhelming. The questions arise – how do we determine what’s meaningful and actionable amidst the sea of information from various sources?

Enter Carevive SMART Data, a game-changer that helps healthcare professionals extract valuable insights from disparate treatment options, drug dosages, interactions, and care delivery data. This digital oncology platform combines EHR-derived clinical data and longitudinal patient-reported outcomes, creating a comprehensive picture of symptoms, disease, and treatment response.

One remarkable example of its utility lies in improved transparency across the care team. Physicians can seamlessly access discrete ePROs data, track trends, and gauge symptom severity, while the nursing team receives proactive notifications, empowering them to engage with patients in real-time and offer personalized care.

Carevive SMART Data streamlines the patient-care team interaction, reducing severe symptoms, hospitalizations, and ultimately improving patient outcomes. By sifting through and identifying the most relevant and actionable data, Carevive SMART Data elevates healthcare decision-making to a whole new level.

Recent Episodes

vitro
View episode

Analyzing the Suppressive TME in In Vitro Based Assays

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

cancer
View episode

Targeting T Cells Within the Cancer Immunity Cycle

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

cancer Immunity cycle
View episode

Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Launch Your Branded Show Today

Engage your audience with original, industry-specific content.

Book a Demo Talk to an Expert